Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

CJC-1295 vs Tesamorelin + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than CJC-1295 (Anecdotal + Phase 2 (DAC)) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. CJC-1295 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

CJC-1295

Anecdotal + Phase 2 (DAC)

Tesamorelin + Ipamorelin

FDA-Approved (component)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

CJC-1295 Tesamorelin + Ipamorelin
Class GHRH analog (no-DAC or DAC forms) FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover.
Route SC injection SC injection
Half-life No-DAC ~30 min / DAC ~8 days Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs
Dosage (research) No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off
Evidence tier Anecdotal + Phase 2 (DAC) FDA-Approved (component)
Research depth 44 indexed (PubMed 34 · CT 1 · EPMC 9) —
Availability Compounding Restricted Compounding Restricted
Reported risks Water retention; numbness/tingling; elevated IGF-1; injection site reactions Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive)

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick CJC-1295 or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than CJC-1295 (Anecdotal + Phase 2 (DAC)) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. CJC-1295 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between CJC-1295 and Tesamorelin + Ipamorelin?

CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: CJC-1295, SC injection; Tesamorelin + Ipamorelin, SC injection.

Which has stronger evidence, CJC-1295 or Tesamorelin + Ipamorelin?

Tesamorelin + Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 44 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page.

Which is more accessible, CJC-1295 or Tesamorelin + Ipamorelin?

Neither CJC-1295 nor Tesamorelin + Ipamorelin is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; Tesamorelin + Ipamorelin, Compounding Restricted. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.

Are CJC-1295 and Tesamorelin + Ipamorelin ever combined?

CJC-1295 and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…